📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-25 18:44
429 analysed today
429
Today
133,318
All-time analysed
40,105
Positive
6,279
Negative
79,121
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
18 announcements match the current filters (relevance ≥ 5).
Noumed Renews 3-Yr OTC Supply Deal in Australia Valued at AUD 30M (₹204 Cr)
Sai Parenterals' Australian subsidiary, Noumed Pharmaceuticals, has renewed its OTC supply contract with a leading Australian pharmacy network for a 3-year term valued at AUD 30 million (~₹204 crore). This adds approximately AUD 10 million (~₹68 crore) in recurring annual revenue and expands the group's total contracted Australian OTC supply book to AUD 232 million (~₹1,506 crore). While current supplies are sourced from third-party manufacturers earning distribution margins, the company plans to transition production to its Adelaide and Indian facilities to capture higher manufacturing margins.
Confidence: HIGH
What changedNoumed Pharmaceuticals renewed an expanded 3-year OTC supply agreement valued at AUD 30 million with a major Australian pharmacy chain.
Why it mattersSecures multi-year revenue visibility (~₹68 crore annually) and reinforces customer retention in the high-barrier Australian regulated market.
Deal value: AUD 30 million (INR 204.0 crore)Contract tenure: 3 yearsAnnual revenue run-rate: AUD 10 millionTotal contracted OTC book: AUD 232 million (INR 1,506 crore)
📅 Short termPositive for sentiment and top-line certainty, though immediate margins will stay distribution-led until in-house manufacturing commences.
📈 Long termStrengthens long-term competitive positioning in Australia; structural margin expansion will depend on internalizing manufacturing across Adelaide and Indian plants.
⚠ Risk flags
- Execution and delay risks in commissioning the Adelaide manufacturing plant
- Third-party sourcing dependency currently constrains profit margins
- Foreign exchange volatility between AUD and INR
Key Highlights
3-year OTC supply contract renewed at AUD 30 million (approximately ₹204 crore)
Translates to an annual contracted run-rate of ~AUD 10 million (~₹68 crore)
Cumulative contracted OTC book in Australia reaches AUD 232 million (~₹1,506 crore)
Plan to shift production in-house upon commissioning of Adelaide plant to boost margins
👀 What to Watch
Track the commissioning timeline of the Adelaide facility and the pace of migrating outsourced volumes to in-house manufacturing to gauge margin expansion.
Sai Parenterals Bags ₹204 Cr (AUD 30M) 3-Year OTC Supply Agreement Renewal in Australia
Sai Parenterals Limited's subsidiary, Noumed Pharmaceuticals Pty Limited, has renewed its OTC medicines supply agreement with a leading Australian pharmacy network. The contract spans a 3-year term starting August 24, 2026, with a projected value of AUD 30 million (~₹204 crore at ₹68.52/AUD). The renewed agreement brings an expanded product portfolio and a higher overall contract value compared to previous terms.
Confidence: HIGH
What changedNoumed Pharmaceuticals Pty Limited secured a 3-year renewal of its OTC supply contract in Australia with an expanded product portfolio and higher value.
Why it mattersProvides ~₹68 crore in annualized projected revenue visibility over the next three years, reinforcing the company's international business footprint.
Total Contract Value: AUD 30 Million (~₹204 Crores)Contract Tenure: 3 yearsEffective Date: 24th August, 2026Exchange Rate: ₹68.52 / AUD
📅 Short termPositive sentiment driver as the renewal secures multi-year international export revenue without disruption.
📈 Long termStrengthens Sai Parenterals' presence in Australia's regulated OTC pharmacy market, offering stable recurring revenue streams.
⚠ Risk flags
- Termination clause allowing cancellation with 6 months' notice prior to expiry
- Foreign exchange fluctuation risks between AUD and INR
Key Highlights
Subsidiary Noumed Pharmaceuticals renewed 3-year supply agreement effective August 24, 2026
Total projected contract value is AUD 30 million (approximately ₹204 crore)
Conversion exchange rate applied is ₹68.52 per AUD
Contract includes an expanded OTC medicines product portfolio with an international pharmacy chain
👀 What to Watch
Track the revenue ramp-up from this expanded contract in upcoming quarterly earnings and monitor margin contributions from Australian subsidiary operations.
Q1 Revenue at Rs 182 Cr; Reallocates Rs 101.85 Cr IPO Funds into Injectables & R&D
Sai Parenterals reported Q1 FY27 consolidated revenue of Rs. 182 crores, EBITDA of Rs. 27 crores (14.9% margin), and PAT of Rs. 8 crores, tracking toward full-year guidance of Rs. 750 crores at ~17% EBITDA margin. The Board approved redeploying Rs. 101.85 crores of IPO proceeds to acquire 60% stakes in Saicriti Pharma (Rs. 83.83 crores) and Prathyak Laboratories (Rs. 15 crores). The shift was driven by Hyderabad Industrial Lands Transformation Policy constraints at its existing sites. The Saicriti investment delivers 154.66 million units of injectable capacity (a 47% increase over original plan) targeting completion by April 2027, while the AUD 53 million Australia capex program remains on track.
Confidence: HIGH
What changedThe company modified its IPO fund deployment strategy from brownfield facility upgrades to acquiring majority stakes in an under-construction injectable facility and an operating R&D lab due to Hyderabad zoning norms.
Why it mattersIncreases planned injectable capacity by 47% to 154.66 million units at the same capex outlay and accelerates complex injectables R&D capability.
Q1 FY27 Consolidated Revenue: Rs. 182 croresFY27 Full Year Revenue Guidance: Rs. 750 croresIPO Proceeds Reallocated: Rs. 101.85 croresSaicriti Injectable Capacity: 154.66 million unitsAustralia Capex Program: AUD 53 million
📅 Short termNear-term focus will be on shareholder voting for the IPO object variation and closing the Prathyak Labs transaction by Q2 FY27.
📈 Long termCommercialization of both the Saicriti critical care facility and the Australian plant by April 2027 sets the platform for substantial scale from FY28 onwards.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution and regulatory audit risks (TGA/USFDA/EU-GMP) for Australian and Saicriti facilities
- Shareholder approval required for variation of IPO issue objects
- Supply chain freight disruptions between India and overseas markets
Key Highlights
Q1 FY27 consolidated revenue stood at Rs. 182 crores with EBITDA of Rs. 27 crores (14.9% margin) and PAT of Rs. 8 crores.
Reaffirmed FY27 revenue target of Rs. 750 crores with an expected EBITDA margin of approximately 17%.
Redeploying Rs. 101.85 crores of IPO funds toward 60% stakes in Saicriti Pharma (Rs. 83.83 crores) and Prathyak Labs (Rs. 15 crores).
Saicriti project delivers 154.66 million units of injectable capacity (+47% vs earlier plan) targeted for completion by April 2027.
Australia AUD 53 million manufacturing facility is fully funded, targeting TGA licensing inspection by March 31, 2027.
👀 What to Watch
Track shareholder approval for the variation in IPO objects, the closing of the Prathyak acquisition by September 30, 2026, and construction progress at the Gummadidala site.
Sai Parenterals: ₹571 Cr Capex and AUD 202m Australia Contract Highlighted in Q1 Presentation
Sai Parenterals has detailed a major structural shift, with export revenue surging from 3% in FY23 to 63% in FY26, primarily driven by the acquisition of Noumed (Australia). The company is executing a ₹571 crore capex program, which is approximately 1.5x its FY26 consolidated revenue of ₹381 crore. Key growth is anchored by a 7.5-year AUD 202 million exclusive supply agreement in Australia and a USD 11 million contract in the Philippines. While revenue grew 58% in FY26, consolidated EBITDA margins compressed to 10.2% from 24.1% in FY25 due to the Noumed integration and acquisition costs.
Confidence: HIGH
What changedThe company has transitioned from a domestic-focused institutional supplier to an export-led CDMO platform with a significant footprint in regulated markets like Australia.
Why it mattersThe massive capex relative to current revenue and long-term international contracts provide high revenue visibility, though the recent margin drop indicates integration challenges that need addressing.
Total Capex Program: ₹571 crCapex vs FY26 Revenue: 149.8%Australia Contract Value: AUD 202 mnFY26 Consolidated Revenue: ₹381.0 crEBITDA Margin (FY26): 10.2%Net Working Capital Days: 196 days
📅 Short termThe market is likely to view the scale of international contracts and the clarity on IPO fund utilization positively over the coming weeks.
📈 Long termStructural shift towards regulated markets and niche injectables could significantly re-rate the business if the ₹571 cr capex translates into high-margin revenue.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant EBITDA margin compression (10.2% vs 24.1% YoY)
- High working capital intensity at 196 days
- Execution risk of large-scale greenfield expansion
Key Highlights
₹571 crore total capex program underway, with ₹440 crore funded by the company through IPO proceeds and grants.
AUD 202 million (approx. ₹1,100+ cr) 7.5-year exclusive supply agreement in Australia effective July 1, 2026.
Export revenue share increased to 63% in FY26 from 3% in FY23, with Australia accounting for 76% of exports.
Installed capacity to expand from 1,160 million units to 1,469 million units p.a. post-expansion program.
CDMO segment now contributes 63% of net revenue, growing at a 355.6% CAGR between FY23 and FY26.
👀 What to Watch
Monitor the execution timeline of the greenfield facility near Hyderabad and the margin recovery trajectory as the high-value Australian contract commences in July 2026.
₹182.4 Cr Revenue in Q1 FY27; Sai Parenterals to Acquire 60% Stakes in Two Pharma Assets
Sai Parenterals reported a consolidated revenue of ₹182.4 crore for Q1 FY27, achieving 24% of its ₹750 crore annual revenue target. The company is pivoting its IPO fund utilization, redeploying ₹101.85 crore to acquire 60% stakes in Saicriti Pharma (a ₹215 crore injectable facility) and Prathyak Laboratories (an established R&D center) instead of greenfield projects. This strategic shift increases planned injectable capacity by 47% to 154.66 million units with only a one-month delay in completion (April 2027). Management maintained its FY27 guidance of ₹750 crore revenue with an EBITDA margin of approximately 17%.
Confidence: HIGH
What changedThe company is shifting from upgrading existing land-constrained units to acquiring majority stakes in a larger, purpose-built injectable facility and an operational R&D center.
Why it mattersThis move bypasses regulatory restrictions at existing sites and accelerates R&D capabilities by acquiring an established team, while providing significantly higher manufacturing capacity for the same capital outlay.
Q1 FY27 Consolidated Revenue: ₹182.4 crFY27 Revenue Guidance: ₹750 crIPO Proceeds Redeployed: ₹101.85 crNew Injectable Capacity: 154.66 million unitsSaicriti Project Total Cost: ₹215 crRedeployment vs FY27 Revenue Target: ~13.6%
📅 Short termThe market is likely to view the strong revenue growth and the strategic pivot toward higher capacity and immediate R&D capabilities as a positive development.
📈 Long termThe acquisition of an established R&D platform and a 47% larger manufacturing base positions the company for structural growth in regulated markets by FY28.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk of the new facility construction
- Regulatory approvals for EU-GMP/USFDA standards
- Integration of newly acquired subsidiaries
Key Highlights
Consolidated revenue reached ₹182.4 crore in Q1 FY27, representing 24% of the ₹750 crore full-year target.
Redeploying ₹83.83 crore of IPO proceeds to acquire a 60% stake in Saicriti Pharma, which is building a ₹215 crore EU-GMP/USFDA compliant facility.
Acquiring a 60% stake in Prathyak Laboratories for ₹18.02 crore, gaining an R&D team of 65 personnel and a pipeline of 150 SKUs.
Injectable capacity target increased by 47% to 154.66 million units compared to the original 105 million units planned in the IPO.
Standalone PAT grew 975.1% YoY to ₹8.9 crore, while consolidated EBITDA margin improved 50 bps QoQ to 14.9%.
👀 What to Watch
Monitor the shareholder approval process for the variation in IPO proceeds and track the construction progress of the Gummadidala facility, targeted for completion by April 2027.
Sai Parenterals Redirects ₹101.86 Cr IPO Funds to Acquire 60% in Saicriti Pharma & Prathyak Labs
Sai Parenterals approved significant alterations to its IPO proceeds utilization, redirecting ₹838.34 million (originally for Unit I & II upgrades) to acquire a 60% stake in Saicriti Pharma, which is setting up a ₹2,149.60 million sterile injectables plant. Additionally, ₹180.23 million earmarked for a new R&D center will be used to acquire a 60% stake in Prathyak Laboratories, an operational R&D platform with 124 product developments. The board also approved key leadership appointments, the resignation of Non-Executive Director Aruna Karusala and the Company Secretary, and the incorporation of a US step-down subsidiary.
Confidence: HIGH
What changedThe company altered its IPO object deployment from internal capex/R&D to acquiring 60% controlling stakes in Saicriti Pharma and Prathyak Laboratories, alongside board/KMP changes.
Why it mattersSwapping organic upgrades for controlling stakes accelerates entry into sterile injectables and R&D capability, but introduces integration risks and requires significant capital commitment.
Saicriti Pharma Stake Acquisition Fund: Rs. 838.34 millionSaicriti Pharma Total Project Cost: Rs. 2,149.60 millionPrathyak Labs Stake Acquisition Fund: Rs. 180.23 millionPrathyak Pipeline Products: 124 products developmentAGM Date: 10th September, 2026
📅 Short termShareholder approval at the September 10 AGM is the immediate milestone to validate the revised deployment of IPO proceeds.
📈 Long termSecuring a dedicated sterile injectables manufacturing facility and an active R&D engine could significantly broaden the global injectable formulation portfolio if executed without cost overruns.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution and funding risk on the ₹214.96 cr Saicriti Pharma greenfield facility
- Shareholder non-approval risk for alteration of IPO terms
- Related-party transaction exposure to loss-making subsidiary Noumed Australia (-₹89.53 million profit/loss)
Key Highlights
₹838.34 million IPO funds redirected to acquire 60% equity in Saicriti Pharma's ₹2,149.60 million greenfield injectables plant in Hyderabad
₹180.23 million IPO funds repurposed to acquire a 60% stake in Prathyak Laboratories with 124 product pipeline
Managing Director Anil Kumar Karusala and WTD Vijitha Gorrepati re-appointed for 3 years starting January 1, 2027
Resignation of Non-Executive Director Aruna Karusala effective August 11, 2026, and CS Shivali Aggarwal on/before October 12, 2026
Approved incorporation of a new step-down subsidiary in the US via Singapore arm and material RPT loan to Noumed Pharmaceuticals Pty Ltd
👀 What to Watch
Track shareholder voting outcomes at the upcoming AGM on September 10, 2026, and monitor the project execution timeline of the ₹214.96 cr Saicriti Pharma injectables facility.
Sai Parenterals to Reallocate Rs 101.8 Cr IPO Funds for 60% Stakes in Two Firms
Sai Parenterals has announced a significant strategic shift, reallocating Rs 101.85 crore of IPO proceeds originally intended for internal upgrades and a new R&D center. The company will now acquire 60% stakes in Saicriti Pharma (injectables plant with a Rs 214.96 cr project cost) and Prathyak Laboratories (R&D platform with 124 products). Additionally, the board approved the incorporation of a US subsidiary and re-appointed key management personnel. However, its Australian step-down subsidiary, Noumed Pharmaceuticals, reported a loss of Rs 8.95 crore on revenue of Rs 103.7 crore for the June 2026 quarter.
Confidence: HIGH
What changedThe company is pivoting from organic growth (upgrading its own units) to inorganic growth by acquiring majority stakes in external manufacturing and R&D entities using IPO proceeds.
Why it mattersThis move accelerates the R&D timeline by acquiring an established platform with 124 products but introduces integration risks and deviates from the original utilization plan disclosed in the March 2026 prospectus.
Total IPO Fund Reallocation: Rs 101.85 crSaicriti Pharma Project Cost: Rs 2,149.60 millionNoumed Australia Q1 Revenue: Rs 1,037.09 millionNoumed Australia Q1 Loss: Rs 89.53 millionPrathyak Labs Product Portfolio: 124 products
📅 Short termThe stock may see volatility as investors digest the shift in IPO fund usage and the loss-making performance of the Australian subsidiary.
📈 Long termIf successfully integrated, the acquisitions could significantly expand the company's injectable capacity and product pipeline, though the turnaround of foreign subsidiaries is critical.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Deviation from IPO prospectus objects
- Loss-making foreign subsidiary
- Related-party loans for downstream funding
- M&A integration risk
Key Highlights
Reallocated Rs 83.83 crore from facility upgrades to acquire 60% of Saicriti Pharma Private Limited.
Reallocated Rs 18.02 crore from a new R&D center to acquire 60% of Prathyak Laboratories, gaining 124 products.
Incorporating a new wholly-owned step-down subsidiary in the United States to expand global operations.
Australian subsidiary Noumed Pharmaceuticals Pty Ltd reported a Q1 loss of Rs 8.95 crore.
Re-appointed Anil Kumar Karusala as Managing Director for 3 years effective January 1, 2027.
👀 What to Watch
Investors should monitor the upcoming Annual General Meeting on September 10, 2026, for shareholder approval of the IPO fund reallocation and the integration timeline for the two new acquisitions. The performance of the loss-making Australian subsidiary remains a key area of concern for consolidated margins.
Rs 101.8 Cr IPO Fund Reallocation for 60% Stakes in Saicriti Pharma and Prathyak Labs
Sai Parenterals has announced a major strategic shift by reallocating Rs 101.85 crore of IPO proceeds to acquire 60% stakes in two entities instead of organic expansion. Rs 83.83 crore will be used to acquire Saicriti Pharma (Greenfield Injectables plant) and Rs 18.02 crore for Prathyak Laboratories (R&D platform with 124 products). The company also reported Q1 FY27 subsidiary performance, where its Australian unit (Noumed) posted a loss of Rs 8.95 crore on revenue of Rs 103.7 crore. Additionally, the board approved the incorporation of a US subsidiary and re-appointed key management personnel for three-year terms.
Confidence: HIGH
What changedThe company has pivoted from upgrading existing facilities and building a greenfield R&D center to acquiring majority stakes in established/developing specialized pharma and R&D entities.
Why it mattersThis inorganic shift aims to reduce execution risk and accelerate time-to-market for 124 R&D products and new injectable capacity, though it increases complexity through new subsidiaries and related-party funding.
Total Reallocated IPO Funds: Rs 101.85 crSaicriti Pharma Project Cost: Rs 214.96 crPrathyak Labs R&D Portfolio: 124 productsNoumed Australia Q1 Revenue: Rs 103.7 crNoumed Australia Q1 Loss: Rs 8.95 cr
📅 Short termThe market is likely to view the acquisition of an R&D platform and new capacity positively, though the loss in the Australian unit may temper enthusiasm.
📈 Long termIf successfully integrated, the 124-product R&D pipeline and the new EU-GMP compliant injectable facility could significantly scale the company's international business.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risk of two simultaneous acquisitions
- Continued losses in the Australian step-down subsidiary
- Related-party loan exposure for overseas funding
Key Highlights
Reallocated Rs 83.83 crore from IPO proceeds to acquire 60% of Saicriti Pharma, replacing the original plan to upgrade Units I and II.
Acquiring 60% of Prathyak Laboratories for Rs 18.02 crore to gain an R&D platform with 124 products in development.
Australian subsidiary Noumed Pharmaceuticals Pty Ltd reported Q1 FY27 revenue of Rs 103.7 crore with a net loss of Rs 8.95 crore.
Total estimated cost for the Saicriti Pharma sterile injectable facility in Hyderabad is Rs 214.96 crore.
Approved a material related party transaction for a loan to the Singapore subsidiary for downstream funding to the Australian unit.
👀 What to Watch
Monitor shareholder approval for the change in IPO object utilization and the subsequent execution timeline for the two acquisitions. Investors should also track the path to profitability for the Australian subsidiary, which is currently a drag on consolidated earnings despite high revenue.
₹1300 Cr (AUD 202M) 7.5-Year Exclusive OTC Supply Deal for Australian Subsidiary
Sai Parenterals' Australian subsidiary, Noumed Pharmaceuticals, has renewed its exclusive OTC supply agreement with a leading pharmacy chain for ₹1300 crores (AUD 202 million). The deal spans 7.5 years starting July 2026, with an estimated annual revenue run rate of approximately ₹174 crores (AUD 27 million). The agreement is structured for compounding growth, targeting 12 new product additions annually and includes a 3-year extension option. This provides the company with exceptional long-term revenue visibility and strengthens its international footprint in a highly regulated market.
Confidence: HIGH
What changedRenewal and expansion of a key international supply contract with a significantly longer tenure (7.5 years) and higher value (₹1300 Cr) compared to previous terms.
Why it mattersIt provides long-term earnings visibility and cements the company's position as a preferred partner in the Australian pharmaceutical retail market, which is known for high regulatory standards.
Total Contract Value: ₹1300 croresContract Tenure: 7.5 yearsAnnualized Revenue: AUD 27 millionNew Product Target: 12 per yearExtension Option: 3 years
📅 Short termThe stock is likely to react positively to the long-term revenue certainty and the scale of the international contract renewal.
📈 Long termThis is a structural positive that builds a predictable revenue base and supports the company's expansion into other regulated global markets like the US or Europe.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution of the 12-product annual launch pipeline
- Regulatory compliance with Australia's TGA
- Currency volatility (AUD/INR)
Key Highlights
Total contract value of AUD 202 million (approx. ₹1300 crores) over a 7.5-year period
Expected annual revenue contribution of roughly AUD 27 million (approx. ₹174 crores)
Built-in growth mechanism targeting the addition of 12 new products to the portfolio every year
Provision for a 3-year extension option beyond the initial 7.5-year term upon mutual consent
Agreement covers the full value chain including manufacturing, TGA registrations, and nationwide distribution
👀 What to Watch
Monitor the company's progress on the 12-product annual launch target and the operationalization of its upcoming Australian manufacturing facility to gauge margin impact.
₹1300 Cr Exclusive OTC Supply Order from Australian Pharmacy Network
Sai Parenterals Limited's subsidiary, Noumed Pharmaceuticals Pty Limited, has secured a massive exclusive supply agreement with a leading Australian pharmacy network. The contract is valued at AUD 202 million, which converts to approximately ₹1300 crores at an exchange rate of 1 AUD = ₹64.5. The agreement is set for a long-term duration of 7.5 years, starting July 1, 2026, with an option for a 3-year extension. This international contract provides significant long-term revenue visibility for the company's Australian operations.
Confidence: HIGH
What changedThe company's subsidiary has transitioned from general operations to securing a major, exclusive long-term supply contract with a dominant market player in Australia.
Why it mattersA ₹1300 crore order provides a stable, long-term revenue floor and validates the company's quality standards in a highly regulated international market like Australia.
Total Order Value (AUD): 202 MillionTotal Order Value (INR): ₹1300 croresContract Duration: 7.5 yearsExchange Rate Used: 1 AUD = ₹64.5Effective Date: 01 July 2026
📅 Short termThe stock is likely to react positively to the news of a large-scale international order win, although the financial impact will only begin to reflect from mid-2026.
📈 Long termThis contract structurally strengthens the company's international business, providing nearly a decade of revenue predictability and potential for further expansion in the Australian market.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk over a 7.5-year period
- Currency fluctuation risk (AUD vs INR)
- Regulatory compliance risks in the Australian pharmaceutical market
Key Highlights
Total contract value of AUD 202 million (approximately ₹1300 crores)
Exclusive OTC medicine supply agreement for a fixed term of 7.5 years
Provision for a 3-year extension upon mutual consent beyond the initial term
Contract execution effective from July 1, 2026
Agreement signed with a leading international pharmacy network in Australia
👀 What to Watch
Investors should monitor the company's capacity expansion plans or capital expenditure required to service this large-scale contract starting in 2026. Watch for future quarterly updates regarding the subsidiary's readiness and any regulatory approvals needed for the specific OTC products.
Sai Parenterals FY26 Revenue Jumps 133% to ₹381 Cr; Targets ₹750 Cr Revenue in FY27
Sai Parenterals reported a transformational FY26 with consolidated revenue growing 133% to ₹381 crore, significantly boosted by the acquisition of Australia-based Noumed Pharmaceuticals. The company is currently executing a ₹440 crore growth capex program, including EU-GMP upgrades in India and a new facility in Adelaide, Australia. Management has issued strong guidance for FY27, targeting ₹750 crore in revenue and 17% EBITDA margins, with FY28 expected to show the full impact of current investments. The integration of Noumed provides access to 451 IP dossiers and major Australian pharmacy networks.
Key Highlights
Consolidated FY26 revenue reached ₹381 crore, up 133% YoY, while standalone PAT grew 64% to ₹17 crore.
Management guidance for FY27 targets ₹750 crore revenue and 17% EBITDA margins.
Executing a ₹440 crore capex program, including ₹111 crore for India upgrades and ₹311 crore for the Adelaide facility.
Acquisition of Noumed Pharmaceuticals adds 451 IP dossiers and distribution access to 2,100 pharmacies in Australia.
Vertical integration benefits and internalization of Noumed's manufacturing are expected to drive significant margin expansion in FY28.
👀 What to Watch
Investors should track the timely commissioning of the Adelaide facility and EU-GMP upgrades in India by Q4 FY27, as these are the primary catalysts for the projected doubling of revenue. The successful integration of Noumed's IP portfolio into the Indian manufacturing base remains a key monitorable for margin improvement.
Sai Parenterals Bags 10-Year Order Worth Rs 104.50 Cr from PILL CORP, Philippines
Sai Parenterals Limited has secured a significant international contract from PILL CORP, Philippines, for the supply of anti-TB products. The contract is valued at USD 11 million, which translates to approximately Rs. 104.50 Crores at an exchange rate of Rs. 95 per USD. This is a long-term agreement spanning 10 years on an exclusivity basis, starting from June 1, 2026. The deal provides long-term revenue visibility and strengthens the company's footprint in the international pharmaceutical market.
Key Highlights
Total contract value of USD 11 million (approximately Rs. 104.50 Crores).
10-year exclusive supply agreement for anti-TB products in the Philippines market.
Contract execution is set to commence on June 1, 2026.
Valuation calculated at a fixed exchange rate of Rs. 95 per USD.
The order is from an international entity with no promoter group interest or related party involvement.
👀 What to Watch
Investors should view this as a positive development for long-term revenue stability; however, they should monitor the execution of periodic purchase orders and the impact of currency fluctuations on margins.
Sai Parenterals FY26 Consolidated Revenue Hits ₹381 Cr; Standalone PAT Jumps 64% YoY
Sai Parenterals reported a strong performance for FY26, with consolidated revenue reaching ₹381 crore, significantly aided by the acquisition of Australia-based Noumed Pharmaceuticals. On a standalone basis, the company saw a robust 64% YoY growth in PAT to ₹17 crore, driven by a massive 250% surge in CDMO revenue. The company successfully listed in April 2026 after a ₹285 crore IPO, utilizing funds for capacity expansion and R&D. With 67 dossiers currently under development and a new facility in Adelaide on track for Q4FY27, the company is aggressively targeting regulated markets.
Key Highlights
Consolidated FY26 revenue reached ₹381 crore, with Q4FY26 contributing ₹198 crore following the Noumed consolidation.
Standalone PAT grew 64% YoY to ₹17 crore, while standalone EBITDA increased 23% to ₹33 crore.
CDMO revenue surged by over 250% YoY, reflecting deeper engagement with global customers and long-term contracts.
Expanded portfolio by 93 dossiers in FY26, with 67 additional dossiers currently under development for export-led growth.
Investing ₹111 crore in Unit III expansion and AUD 53 million for a new TGA-approved facility in Australia.
👀 What to Watch
Investors should focus on the successful integration of Noumed and the ramp-up of the CDMO business which is driving higher margins. The progress of the Adelaide facility and EU-GMP upgradations of Indian units are key catalysts for future valuation re-rating.
Sai Parenterals Q4 PAT Surges 736% to ₹13.25 Cr; FY27 Revenue Target Set at ₹750 Cr
Sai Parenterals reported an exceptional Q4 FY26 with PAT surging 736% YoY to ₹13.25 crore, driven by the successful integration of Noumed (Australia) and a 250% jump in CDMO revenues. Full-year FY26 revenue grew 140% to ₹380.99 crore, reflecting the impact of strategic acquisitions and export growth. The company successfully completed its IPO in March 2026, raising ₹285 crore to fund a massive ₹440 crore capex program. Management has issued aggressive guidance for FY27, targeting ₹750 crore in revenue and an improved EBITDA margin of 17%.
Key Highlights
Q4 FY26 revenue grew 166.65% YoY to ₹197.93 Cr, while PAT increased 736.04% to ₹13.25 Cr.
FY26 consolidated revenue reached ₹380.99 Cr (+140.37% YoY) following the acquisition of Noumed Australia.
Management targets FY27 revenue of ₹750 Cr and EBITDA margins of 17%, nearly doubling current revenue levels.
Ongoing capex of ₹440 Cr includes a new R&D center in India and Australia's largest modern pharmaceutical plant.
CDMO revenues surged by over 250% YoY, supported by 88 new product dossiers added in FY26 and 67 more in the pipeline.
👀 What to Watch
Investors should focus on the company's ability to execute its ₹440 crore capex and achieve the ambitious ₹750 crore revenue target for FY27. The stock remains a high-growth play in the CDMO and injectable space following its recent listing and successful Australian integration.
Sai Parenterals Reports Zero Deviation in Utilization of ₹2,850 Million IPO Proceeds
Sai Parenterals Limited has submitted its statement of deviation for the quarter and year ended March 31, 2026, confirming that IPO funds are being handled as per the offer document. The company raised ₹2,850 million through its Initial Public Offer in late March 2026. As of the reporting date, no funds have been diverted from their original objects, which include significant allocations for capacity expansion and debt repayment. The monitoring agency, India Ratings & Research, and the company's Audit Committee have reviewed and confirmed the status.
Key Highlights
Successfully raised ₹2,850 million through an IPO conducted between March 24 and March 27, 2026.
Confirmed zero deviation or variation in the utilization of proceeds for the period ending March 31, 2026.
Major allocations include ₹1,107.95 million for capacity expansion and ₹356.41 million for loan repayments related to the acquisition of Noumed Pharmaceuticals (Australia).
Allocated ₹180.23 million for the establishment of a new R&D Centre and ₹330 million for working capital requirements.
India Ratings & Research Private Limited is acting as the monitoring agency for the fund utilization.
👀 What to Watch
Investors should track subsequent quarterly filings to ensure the ₹2,850 million is deployed timely into the high-growth capacity expansion and R&D projects as promised.
Sai Parenterals Reports Q3 FY26 Consolidated PAT of ₹33.37 Million Post-IPO
Sai Parenterals Limited has released its first set of financial results post-listing for the quarter and nine months ended December 31, 2025. On a consolidated basis, the company reported a revenue of ₹892.11 million for the quarter, though it faced a loss before tax of ₹16.25 million, which turned into a PAT of ₹33.37 million due to deferred tax credits. The standalone performance remained profitable with a nine-month PAT of ₹68.28 million. A significant development is the completed acquisition of a 74.64% stake in UK-based Noumed Life Sciences for AUD 22 million, which is now reflected in the consolidated figures.
Key Highlights
Consolidated Revenue from Operations for Q3 FY26 stood at ₹892.11 million.
Consolidated Profit After Tax (PAT) for the quarter was ₹33.37 million, supported by a ₹55.57 million deferred tax credit.
Standalone Nine-Month revenue reached ₹1,054.59 million with a PAT of ₹68.28 million.
Completed acquisition of 74.64% stake in Noumed Life Sciences Limited (UK) for an aggregate consideration of AUD 22 million.
The company reported an unmodified audit opinion for the financial year ended March 31, 2026.
👀 What to Watch
Investors should closely monitor the operational integration of the UK-based Noumed Life Sciences, as the consolidated entity is currently reporting losses at the pre-tax level despite high revenue scaling. The stock's performance will likely depend on the company's ability to turn the consolidated operations profitable without relying on tax adjustments.
Sai Parenterals Q3 FY26 Consolidated Revenue at ₹892.1M; Completes Noumed UK Acquisition
Sai Parenterals reported a consolidated revenue of ₹892.11 million for the quarter ended December 31, 2025, with a net profit of ₹33.37 million. The standalone performance for the same quarter showed a revenue of ₹384.79 million and a profit of ₹3.63 million. A major strategic milestone was the completion of a 74.64% stake acquisition in UK-based Noumed Life Sciences Limited for AUD 22 million. As the company was recently listed, year-on-year comparative figures for the previous financial year are not available.
Key Highlights
Consolidated revenue for Q3 FY26 reached ₹892.11 million with a PAT of ₹33.37 million.
Standalone 9-month revenue stood at ₹1,054.59 million with a PAT of ₹68.28 million.
Completed acquisition of 74.64% stake in Noumed Life Sciences (UK) for a total consideration of AUD 22 million.
Consolidated 9-month revenue reported at ₹1,530.71 million, indicating strong contribution from international subsidiaries.
Statutory auditors issued an unmodified opinion on the audited financial results for the year ended March 31, 2026.
👀 What to Watch
Investors should monitor the integration of the Noumed UK acquisition and its impact on consolidated margins in future quarters. As a newly listed entity, focus on the company's ability to maintain revenue growth in the branded generic and CDMO segments.
Sai Parenterals Approves INR 11.91 Cr Loan for Australian Subsidiary Expansion
The Board of Sai Parenterals has approved an unsecured loan of up to AUD 1.75 million (approximately INR 11.91 crore) to its wholly-owned subsidiary, Sai Singapore Pte. Ltd. These funds are designated for downstream investment into Noumed Pharmaceuticals PTY Limited, the company's step-down subsidiary in Australia. This move signifies a strategic effort to bolster its international operations and provide financial support to its Australian business unit. The transaction highlights the company's focus on global market penetration through its existing subsidiary network.
Key Highlights
Approved financial assistance via unsecured loan not exceeding AUD 1.75 million or SGD 1.610 million.
Total investment value is approximately INR 11,91,40,000.
Funds to be routed through Sai Singapore Pte. Ltd. to Noumed Pharmaceuticals PTY Limited, Australia.
The board meeting concluded on April 20, 2026, confirming the strategic capital allocation.
👀 What to Watch
Investors should monitor the revenue contribution from the Australian subsidiary in future earnings to evaluate the effectiveness of this capital infusion. The stock remains a positive watch for those tracking the company's international growth trajectory.
